Jubilant Pharmova Limited (BOM:530019)
India · Delayed Price · Currency is INR 1,023.95
+1.70 (0.17%)
At close: Jul 20, 2026
Jubilant Pharmova Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 14% in FY 2026, led by CDMO Sterile Injectables and Radiopharma, but EBITDA margins declined due to supply issues. FY 2027 will see margin pressure in H1, with recovery in H2 as Montreal stabilizes. Major CapEx is focused on expanding biologics and sterile injectables capacity.